CHRS Stock Recent News

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securities Michael Nedelcovych - TD Cowen Colleen Kusy - Robert W.

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago.

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Rosh Dias - Chief Medical Officer Theresa LaVallee - Chief Development Officer Bryan McMichael - Interim Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Colleen Kusy - Baird Operator Ladies and gentlemen, thank you for standing by.

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.75 per share a year ago.

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale.